OBSOLETE: HIV-related vulvovaginal cancer

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:443319
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

This entry, listed under the Orphanet code 443319, is marked as OBSOLETE and refers to a condition once described as 'HIV-related vulvovaginal cancer.' This means it was previously used to describe cancers of the vulva (the outer female genitalia) or vagina that occurred in people living with HIV (Human Immunodeficiency Virus). Because HIV weakens the immune system, people living with HIV have a higher risk of developing certain cancers, including those caused by the Human Papillomavirus (HPV), such as vulvar and vaginal cancers. This specific disease classification has since been retired or reorganized in medical databases. The underlying conditions it referred to — vulvar cancer and vaginal cancer in the context of HIV — are now typically classified and managed under broader cancer and HIV-related illness categories. Symptoms of vulvovaginal cancer can include unusual lumps or sores on the vulva or vagina, persistent itching or burning, abnormal bleeding not related to periods, and pain during sex or urination. Because this is an obsolete classification, patients and caregivers should speak with their doctors about current, up-to-date diagnostic categories. Treatment for vulvovaginal cancers generally includes surgery, radiation therapy, and sometimes chemotherapy, depending on the stage and location of the cancer. HIV management with antiretroviral therapy (ART) is also a critical part of care, as keeping the immune system strong can improve cancer treatment outcomes.

Key symptoms:

Unusual lumps, bumps, or warts on the vulva or vaginaPersistent itching, burning, or soreness in the genital areaAbnormal vaginal bleeding not related to menstrual periodsPain or discomfort during sexPain or burning when urinatingSkin color changes or thickening on the vulvaOpen sores or ulcers in the genital area that do not healSwollen lymph nodes in the groinUnusual vaginal discharge

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: HIV-related vulvovaginal cancer.

View clinical trials →

No actively recruiting trials found for OBSOLETE: HIV-related vulvovaginal cancer at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: HIV-related vulvovaginal cancer community →

No specialists are currently listed for OBSOLETE: HIV-related vulvovaginal cancer.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: HIV-related vulvovaginal cancer.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: HIV-related vulvovaginal cancerForum →

No community posts yet. Be the first to share your experience with OBSOLETE: HIV-related vulvovaginal cancer.

Start the conversation →

Latest news about OBSOLETE: HIV-related vulvovaginal cancer

No recent news articles for OBSOLETE: HIV-related vulvovaginal cancer.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Is this cancer related to my HIV, and how does my HIV status affect my treatment options?,What stage is my cancer, and what does that mean for my treatment and outlook?,Should I change or adjust my HIV antiretroviral therapy during cancer treatment?,What are the side effects of the recommended cancer treatments, and how can they be managed?,How often will I need follow-up appointments and screenings after treatment?,Are there clinical trials available for people living with HIV who have this type of cancer?,What support services — such as counseling, nutrition advice, or support groups — are available to me?

Common questions about OBSOLETE: HIV-related vulvovaginal cancer

What is OBSOLETE: HIV-related vulvovaginal cancer?

This entry, listed under the Orphanet code 443319, is marked as OBSOLETE and refers to a condition once described as 'HIV-related vulvovaginal cancer.' This means it was previously used to describe cancers of the vulva (the outer female genitalia) or vagina that occurred in people living with HIV (Human Immunodeficiency Virus). Because HIV weakens the immune system, people living with HIV have a higher risk of developing certain cancers, including those caused by the Human Papillomavirus (HPV), such as vulvar and vaginal cancers. This specific disease classification has since been retired or

At what age does OBSOLETE: HIV-related vulvovaginal cancer typically begin?

Typical onset of OBSOLETE: HIV-related vulvovaginal cancer is adult. Age of onset can vary across affected individuals.